PB
PBIO.US Pressure Biosciences Inc
- Market cap
- USD 8.19K
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2024.
Is PBIO.US undervalued?
Graham numberThe Graham number of Pressure Biosciences Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Pressure Biosciences Inc fundamental analysis
No fundamental analysis for Pressure Biosciences Inc yet.
Pressure Biosciences Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Pressure Biosciences Inc
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lo…
Full company profilePressure Biosciences Inc financial statements
2024 annualized: Fiscal year 2024 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2024, the balance sheet is the latest quarter. Figures change when the annual report is published.
Pressure Biosciences Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.37M | 1.80M | 1.98M | 2.24M | 2.46M | 1.81M | 1.22M | 2.00M | 1.73M | 1.98M | 1.54M |
| Gross Profit | 1.37M | 83.3K | 1.14M | 967K | 1.18M | 613K | 638K | 1.06M | -285K | 800K | 320K |
| Operating Income | -3.34M | -3.57M | -3.74M | -4.65M | -4.48M | -5.81M | -4.59M | -4.19M | -4.90M | -9.50M | -6.83M |
| EBITDA | - | - | - | -4.65M | -5.44M | -6.47M | -7.53M | -5.59M | -5.52M | -13.6M | - |
| Net Income | -4.61M | -7.42M | -2.71M | -10.7M | -9.70M | -11.7M | -16.0M | -20.2M | -16.1M | -29.3M | -30.4M |
| EPS | -0.25 | - | -0.09 | -7.98 | -5.76 | -4.57 | -3.84 | -2.21 | -1.17 | -0.83 | -0.56 |
| Balance Sheet | |||||||||||
| Total Assets | 1.74M | 1.80M | 1.63M | 2.16M | 2.40M | 1.82M | 2.30M | 2.83M | 2.01M | 1.05M | 6.88M |
| Total Liabilities | 3.80M | 9.78M | 10.0M | 16.8M | 8.52M | 13.9M | 19.2M | 25.0M | 34.7M | 33.8M | 44.1M |
| Shareholders' Equity | -2.06M | -7.98M | -8.38M | -14.6M | -6.13M | -12.1M | -16.9M | -22.2M | -32.7M | -32.8M | -37.2M |
| Cash & Short-term Investments | 474K | 117K | 138K | 81.0K | 103K | 29.6K | 18.5K | 132K | 3.87K | 81.3K | 14.3K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.21M | -3.82M | -3.81M | -3.90M | -5.70M | -6.33M | -4.88M | -4.87M | -4.48M | -3.19M | -5.13M |
| Capital Expenditure | 7.14K | 9.41K | 7.20K | 21.8K | 23.4K | 23.4K | 1.66K | 123K | 20.8K | 7.50K | 0.00 |
| Free Cash Flow | - | - | - | -4.08M | -5.70M | -6.35M | -4.88M | -4.99M | -4.50M | -3.19M | -5.13M |
| Ratios | |||||||||||
| ROA | -264.5% | -411.0% | -166.5% | -496.0% | -404.2% | -642.1% | -695.1% | -711.5% | -800.0% | -2,792.7% | -441.6% |
| Net Profit Margin | -335.5% | -412.5% | -137.0% | -478.3% | -394.6% | -644.3% | -1,311.3% | -1,006.5% | -929.6% | -1,482.2% | -1,970.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Pressure Biosciences Inc dividends
Pressure Biosciences Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Jun 5, 2017.
Who owns Pressure Biosciences Inc
- Insiders 0.70%
- Institutions 0.00%
- Public & others 99.30%
- Shares outstanding 41.0M
- Free float 40.7M
Pressure Biosciences Inc company profile
- Company name
- Pressure Biosciences Inc
- Ticker
- PBIO.US
- Exchange
- USA Stocks
- Listed since
- Oct 31, 1996
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 15
- Fiscal year end
- December
- Address
- 480 Neponset Street, Canton, MA, United States, 02021
- Phone
- 508 230 1828
- Website
- pressurebiosciences.com
About Pressure Biosciences Inc
Pressure BioSciences, Inc. develops and sells high pressure technology-based instruments, consumables, and services for life sciences and other industries worldwide. The company's products/services are based on Ultra Shear Technology platform, which turns hydrophobic oil-based supplements, therapeutics, and other active ingredients to water-soluble, bioavailable, oil-in-water nano emulsion formulations; BaroFold Technology platform, that is used to improve the quality and lower the production costs of protein biotherapeutics; and Pressure Cycling Technology platform which uses alternating cycles of hydrostatic pressure between ambient and ultra-high pressures to control bio-molecular interactions in sample preparation. It offers Barocycler instrumentations comprising Barocycler 2320EXT, Barocycler HUB440, Barocycler HUB880, and the Shredder SG3; Barocycler consumable products, such as PCT MicroTubes, PCT MicroCaps, and PCT-Micro Pestle; UltraShear Mini, UltraShear K45, and UltraShear Max; and application specific kits, as well as consumable products. The company also provides pain relief, skincare solutions, personal wellness, athletic recovery, and specialized pet care products. It serves researchers at academic laboratories, government agencies, biotechnology and pharmaceutical companies, other life science institutions, and food/beverages laboratories. The company has collaborations with RedShiftBio Inc.; Inova Schar Cancer Center; NYU; Leica Microsystems, GmbH; The Ohio State University; University of Delaware; and Cedars Sinai Medical Center. The company was formerly known as Boston Biomedica, Inc. and changed its name to Pressure BioSciences, Inc. in September 2014. Pressure BioSciences, Inc. was incorporated in 1978 and is headquartered in Canton, Massachusetts.
Pressure Biosciences Inc management
4- Mr. Richard T. SchumacherFounder, President, CEO, Treasurer, Interim CFO, Clerk & Director · born 1950
- Dr. Edmund Y. Ting Ph.D., Sc.D. Ph.D.Senior Vice President of Engineering · born 1955
- Dr. Alexander V. Lazarev Ph.D.Chief Science Officer · born 1965
- Mr. John B. HollisterDirector of Sales & Marketing